[{"id":"c806a099-ac30-4f24-bc10-a04a25d2bf23","acronym":"GEMINI-Gastric","url":"https://clinicaltrials.gov/study/NCT05702229","created_at":"2023-11-09T18:13:01.598Z","updated_at":"2025-02-25T15:13:18.164Z","phase":"Phase 2","brief_title":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT05702229 - GEMINI-Gastric","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 01/16/2023","start_date":" 01/16/2023","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/28/2027","study_completion_date":" 01/28/2027","last_update_posted":"2025-02-13"},{"id":"e5e3ad81-9df9-4560-a791-5e9b3953d9ad","acronym":"KYM901","url":"https://clinicaltrials.gov/study/NCT04805307","created_at":"2021-03-18T11:52:24.597Z","updated_at":"2025-02-25T15:19:03.220Z","phase":"Phase 1","brief_title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901","source_id_and_acronym":"NCT04805307 - KYM901","lead_sponsor":"Keymed Biosciences Co.Ltd","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sonesitatug vedotin (AZD0901)"],"overall_status":"Completed","enrollment":" Enrollment 176","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 04/05/2024","primary_completion_date":" 04/05/2024","study_txt":" Completion: 04/05/2024","study_completion_date":" 04/05/2024","last_update_posted":"2025-02-12"},{"id":"d1fb7474-3dd7-44b8-b923-5fc52d65fdb6","acronym":"CLARITY-PanTumor01","url":"https://clinicaltrials.gov/study/NCT06219941","created_at":"2024-01-23T20:21:10.317Z","updated_at":"2024-07-02T16:34:26.279Z","phase":"Phase 2","brief_title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","source_id_and_acronym":"NCT06219941 - CLARITY-PanTumor01","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • leucovorin calcium • sonesitatug vedotin (AZD0901) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 01/19/2027","study_completion_date":" 01/19/2027","last_update_posted":"2024-06-13"}]